sur PREDILIFE (EPA:ALPRE)
Major validation of the MammoRisk strategy against breast cancer
PREDILIFE announces a significant advance in breast cancer screening. The results of the WISDOM study, published in JAMA, confirm the effectiveness of risk-based screening strategies. This randomized study included more than 28,000 women aged 40 to 74. It compared standard annual screening with personalized screening based on individual risk.
Advanced-stage breast cancer decreased by 37.5% in the group receiving personalized screening. In Europe, the approach is being evaluated in the MyPeBS study of 53,000 women, using Predilife's MammoRisk test. MammoRisk, whose performance has been validated in the UK, is based on a US model of nearly one million women.
These results reinforce PREDILIFE's commitment to deploying these personalized approaches in Europe and the United States.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PREDILIFE